CLZ 2002
Alternative Names: CLZ-2002Latest Information Update: 21 Jul 2023
At a glance
- Originator Cellatoz Therapeutics
- Class Cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Charcot-Marie-Tooth disease
- Preclinical Carpal tunnel syndrome; Spinal cord injuries
Most Recent Events
- 20 Jul 2023 Preclinical trials in Carpal tunnel syndrome in South Korea (unspecified route) (Cellatoz Tx Pipeline, July 2023)
- 20 Jul 2023 Preclinical trials in Spinal cord injuries in South Korea (unspecified route) (Cellatoz Tx Pipeline, July 2023)
- 19 Jun 2023 Phase-I clinical trials in Charcot-Marie-Tooth disease in South Korea (IM) (NCT05947578)